Daiichi Seeks High Court Review Of Panel’s Reversal In Patent Drug Dispute
(September 16, 2015, 4:10 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court should review a drug patent infringement lawsuit over Apotex Inc.’s efforts to end Mylan Pharmaceuticals Inc.’s generic exclusivity for “Benicar” hypertension drug through a noninfringement decision, a drug manufacturer says in a Sept. 4 petition for certiorari, arguing that the lawsuit should be tossed based on Article III of the Constitution (Daiichi Sankyo, Inc. and Daiichi Sankyo Co., Ltd. v. Apotex, Inc., No. 15-281, U.S. Sup.).
(Petition for writ of certiorari available. Document #78-150921-009B.)